Alexander E Perl
Overview
Explore the profile of Alexander E Perl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
4896
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schlenk R, Montesinos P, Kim H, Romero-Aguilar A, Vrhovac R, Patkowska E, et al.
Haematologica
. 2025 Mar;
PMID: 40079105
QuANTUM-First (NCT02668653) was a randomized phase 3 trial in newly diagnosed FLT3-ITDQpositive acute myeloid leukemia (AML) patients treated with quizartinib or placebo plus standard induction and consolidation chemotherapy and/or allogeneic...
2.
Jillella A, Lee S, Altman J, Luger S, Tallman M, Foran J, et al.
JAMA Oncol
. 2025 Feb;
PMID: 40014329
Importance: Acute promyelocytic leukemia (APL) is an acute illness that presents with cytopenia, infections, and disseminated intravascular coagulation. Achieving remission has been shown to make a major difference in patient...
3.
Wang X, Gimotty P, Matthews A, Mamtani R, Luger S, Hexner E, et al.
Blood Adv
. 2025 Jan;
9(3):533-544.
PMID: 39888631
Little is known about the impact of recent advances in acute myeloid leukemia (AML) treatment on racial/ethnic disparities in survival outcomes. We performed a retrospective cohort study of patients with...
4.
Levis M, Hamadani M, Logan B, Jones R, Singh A, Litzow M, et al.
Blood
. 2025 Jan;
PMID: 39775763
BMT CTN 1506 ("MORPHO"; NCT02997202) was a randomized phase 3 study of gilteritinib compared to placebo as maintenance therapy after hematopoietic stem cell transplantation (HCT) for patients with FLT3-ITD-mutated acute...
5.
Perl A
Blood
. 2024 Nov;
PMID: 39541573
Combining FLT3 inhibitors with intensive chemotherapy and transplant has substantially improved AML outcomes, prompting a recent re-evaluation of FLT3-ITD's historically negative prognostic effect. Treatment approaches may soon undergo major changes...
6.
Brown F, Wang X, Birkinshaw R, Chua C, Morley T, Kasapgil S, et al.
Blood Adv
. 2024 Oct;
9(1):127-131.
PMID: 39374584
No abstract available.
7.
Bhagwat A, Torres L, Shestova O, Shestov M, Mellors P, Fisher H, et al.
Nat Med
. 2024 Sep;
30(12):3697-3708.
PMID: 39333315
Acute myeloid leukemia (AML) is a rapidly progressive malignancy without effective therapies for refractory disease. So far, chimeric antigen receptor (CAR) T cell therapy in AML has not recapitulated the...
8.
Peretz C, Kennedy V, Walia A, Delley C, Koh A, Tran E, et al.
Nat Commun
. 2024 Sep;
15(1):8191.
PMID: 39294124
Despite recent work linking mixed phenotype acute leukemia (MPAL) to certain genetic lesions, specific driver mutations remain undefined for a significant proportion of patients and no genetic subtype is predictive...
9.
Hamilton B, Pandya B, Ivanescu C, Elsouda D, Hamadani M, Chen Y, et al.
Blood Adv
. 2024 Aug;
8(19):5091-5099.
PMID: 39167766
The Blood and Marrow Transplant (BMT) Clinical Trials Network conducted a phase 3 randomized trial comparing gilteritinib with placebo after allogeneic hematopoietic cell transplantation (HCT) for FLT3-ITD+ acute myeloid leukemia...
10.
Connor M, Prathapa N, Frey N, Gill S, Hexner E, Bruno X, et al.
Haematologica
. 2024 Apr;
109(8):2732-2737.
PMID: 38634143
No abstract available.